Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-20
2008-05-20
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S185100, C536S023200, C435S196000
Reexamination Certificate
active
09854356
ABSTRACT:
The present invention is generally directed to HER-2
eu fusion proteins, nucleic acid molecules encoding HER-2
eu fusion proteins, viral vectors expressing HER-2
eu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2
eu fusion proteins and/or nucleic acid molecules encoding the HER-2
eu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2
eu protein, including for uses in the treatment of malignancies associated with the HER-2
eu oncogene.
REFERENCES:
patent: 4803072 (1989-02-01), Dalton et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 5976546 (1999-11-01), Laus et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6270769 (2001-08-01), Raychaudhuri et al.
patent: 6287569 (2001-09-01), Kipps et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6664370 (2003-12-01), Cheever et al.
patent: 6734172 (2004-05-01), Scholler et al.
patent: 6942862 (2005-09-01), Cheever et al.
patent: 6953573 (2005-10-01), Cheever et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 0 474 727 (1997-07-01), None
patent: 0735898 (1999-10-01), None
patent: 0 444 181 (2001-10-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO91/18926 (1991-12-01), None
patent: WO 91/18926 (1991-12-01), None
patent: WO 95/17210 (1995-06-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO96/02555 (1996-02-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/30514 (1996-10-01), None
patent: WO98/25574 (1998-08-01), None
patent: WO 99/46988 (1999-09-01), None
patent: WO99/57981 (1999-11-01), None
patent: WO00/04927 (2000-02-01), None
patent: WO00/20027 (2000-04-01), None
patent: WO00/29582 (2000-05-01), None
patent: WO 00/44899 (2000-08-01), None
patent: WO 01/74855 (2001-10-01), None
Wang, J. et al. 2000 J. Biol. Chem. 275 (1):507-513.
Sequence alignment for SEQ ID NOS: 6 (p. 1) and 7 (p. 1).
Stedman's Medical Dictionary- “vaccine” (p. 1).
NCI Dictionary- “vaccine” (p. 1).
Limentani et al. (Poster Abstract)- Oct. 26-28, 2006.
Disis, Mary L. et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein”,The Journal of Immunology, 1996, pp. 3151-3158, vol. 156, The American Association of Immunologists.
Cornelia I. Bargmann et al., “TheNeuOncogene Encodes an Epidermal Growth Factor Receptor-Related Protein,” Jan. 1986, Nature, vol. 319, pp. 226-230.
Yasuhiro Nagata et al., “Peptides Derived From a Wild-Type Murine Proto-Oncogene c-erbB-2/HER2
euCan Induce CTL and Tumor Suppression in Syngeneic Hosts,” 1997, The American Association of Immunologists, The Journal of Immunology 159: 1336-1343.
Disis, et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein”;The American Association of Immunologistspp. 3151-3158 (1996).
Disis—Abstract 2709; Abstracts from Meetings in New Orleans, Jun. 2-6, 1996, The FASEB Journal, 10(6):A1470 (1996).
Dermer, Another Anniversary for the War on Cancer, Bio/Technology 12:320 (1994).
Spitler, Cancer Vaccines: The Interferon Analogy, Cancer Biotherapy 10(1):1-3 (1995).
Osband and Ross, Problems in Investigational Study and Clinical Use of Cancer Immunotherapy, Immunology Today 1(6):193-195 (1990).
Bernhard et al., Vaccination against the HER-2
eu oncogenic protein, Endocrine-Related Cancer 9:33-44 (2002).
Chamberlain et al., Innovation and strategies for the development of anticancer vaccines, Expert Opinion on Pharmacotherapy 1(4):603-614 (2000).
Disis and Cheever, HER-2
eu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer, Advances in Cancer Research 71:343-371 (1997).
Ezzell, Cancer “Vaccines”: An Idea Whose Time Has Come?, Journal of NIH Research 7:46-49 (1995).
Chamberlain and Kaufman; Innovations and strategies for the development of anticancer vaccines; Expert Opinion on Pharmacotherapy; 2000; 1/4; 603-614.
Disis and Grabstein; Generationn of Immunity to the HER-2
eu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine; Clinical Cancer Research; Jun. 1999; 5; 1289-1297.
Disis and Cheever; HER-2
ew Protein: A Target for Antigen-specific Immunotherapy of Human Cancer; Advances in Cancer Research; 1997; 71; 343-371.
Ezzel et al.; Cancer Vaccines—An Idea Whose Time has Come?; J. NIH Research; 1995; 7; 46-49.
Kurebayashi; Biological and Clinical Significance of HER2 Overexpression in Breast Cancer; Breast Cancer; Jan. 2001; 8/1; 45.
Limentani et al.; A recombinant HER2 protein evaluated for cancer immunotherapy: induction of specific antibodies and T-cells; (Poster) 18th EORTC-NCI-AACR Symposium, Prague, CZ; Nov. 7-11, 2006.
Limentani et al.; Evaluation of a recombinent HER2 vaccine: Induction of specific antibodies, T-cells and preliminary activity in metastitic breast cancer patients; J. Clinical Oncology (Abstract, 2006 ASCO Annual Meeting); Jun. 20, 2006; 631.
Murray et al.; Clinical Trials of Her2
eu specific vaccines.; Seminars in Oncology; Dec. 2000; 27/6 Supp 11; 71-75.
Ross and Fletcher; The HER-2
eu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy; The Oncologist; 1998; 3; 237-252.
Sikic; New approaches in cancer treatment; Annals of Oncology; 1999; 10(Suppl 6); S149-S153.
Zaks and Rosenberg; Immunization with a Peptide Epitope (p. 369-377) from HER-2
eu Leads to Peptide-specific Cytotoxic T Lymphocytes That Fail to Recognize HEr-2
eu+ Tumors; Cancer Research; Nov. 1, 1998; 58; 4902-4908.
Cheever Martin A.
Gheysen Dirk
Bristol Lynn
Campen Virginia G.
Corixa Corporation
Helms Larry R.
SmithKline Beecham Biologicals (s.a.)
LandOfFree
HER-2/neu fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HER-2/neu fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HER-2/neu fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930105